Penicillin V Potassium
- Atc Codes:J01CE
- CAS Codes:132-98-9#87-08-1
- PHARMGKB ID:132-98-9#87-08-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ospen, Penstad V; Belgium: Peni Oral; Cyprus: Orvek, Ospa-V, Robicillin VK; Finland: Milcopen; France: Oracilline; Germany: Penicillin V; Greece: Ospen; Hungary: Ospen, Vegacillin; Ireland: Calvepen, Kopen Penicillin VK; Italy: Fenospen; Luxembourg: Peni Oral; Netherlands: Acipen, Penicilline V; Poland: Ospen; Spain: Penilevel Oral; UK: Apsin, Phenoxymethylpenicillin, Tenkicin.
North America
Canada: Apo-Pen VK, Novo-Pen-VK, Nu-Pen-VK; USA: Veetids.
Latin America
Argentina: Fenoximetilpenicilina, Pen Oral, Penfantil Oral, Penicilina Oral, Penicilina V; Brazil: Fenoximetilpenicilina, Fenoximetilpenic. Potássica, Meracilina, Oracilin, Pencilin-V, Penicigran, Pen-V-Cil, Pen-Ve-Oral; Mexico: Anapenil, Pota-Vi-Kin.
Drug combinations
Chemistry
Penicillin V Potassium: C~16~H~17~KN~2~O~5~S. Mw: 388.48. (1) 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-, monopotassium salt, [2S-(2α,5α,6β)]-; (2) Monopotassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. CAS-132-98-9; CAS-87-08-1(penicillin V)(1975).
Pharmacologic Category
Natural Penicillins. (ATC-Code: J01CE).
Mechanism of action
Inhibits bacterial cell wall synthesis by binding to one or more penicillin-binding proteins. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.
Therapeutic use
Treatment of infections caused by susceptible organisms involving respiratory tract, otitis media, sinusitis, skin, and urinary tract. Prophylaxis in rheumatic fever.
Pregnancy and Lactation Implications
Adverse events not observed in animal studies. No evidence of adverse fetal effects after penicillin use during pregnancy in humans. Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of penicillin V may be altered in 2^nd^ and 3^rd^ trimester. Caution when administering penicillin to nursing women.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to penicillin or any component of the formulation.
Warnings and precautions
Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions reported, especially with history of β-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (use with caution in asthmatic patients). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in severe renal impairment, and in history of seizure disorder (high levels, particularly in presence of renal impairment, may increase risk of seizures). Prolonged use or use associated with high serum concentrations (e.g. in renal insufficiency) may be associated with increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).